New Pneumococcal Vaccine CAPVAXIVE Approved by FDA

The U.S. Food and Drug Administration has approved CAPVAXIVE for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae in individuals 18 years of age and older.

First Vaccine for Mosquito-Born Viral Disease Is Approved by FDA

The U.S. Food and Drug Administration has approved IXCHIQ, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.